Abstract
Cognitive impairment (CI) has been recognized as a core feature of Alzheimers disease (AD) and schizophrenia. The 5-HT6 receptor is an attractive target for the development of cognitive enhancers due to its unique localization and pharmacology. 5-HT6 receptor antagonists have been shown to modulate multiple neurotransmitter systems and therefore enhance cognition in preclinical studies. This premise translated into the clinical efficacy of the 5- HT6 receptor antagonist SB-742457 in mild-to-moderate AD patients. Advances in the understanding of the structureactivity- relationship, the design of novel 5-HT6 receptor ligands and their potential application for the treatment of CI are reviewed.
Keywords: Serotonin, G-Protein coupled receptor, medicinal chemistry, chemical biology, drug design, Alzheimer's disease, schizophrenia, neurological disorders
Current Topics in Medicinal Chemistry
Title: 5-HT6 Receptor Antagonists as Potential Therapeutics for Cognitive Impairment
Volume: 10 Issue: 2
Author(s): Gerard Rosse and Herve Schaffhauser
Affiliation:
Keywords: Serotonin, G-Protein coupled receptor, medicinal chemistry, chemical biology, drug design, Alzheimer's disease, schizophrenia, neurological disorders
Abstract: Cognitive impairment (CI) has been recognized as a core feature of Alzheimers disease (AD) and schizophrenia. The 5-HT6 receptor is an attractive target for the development of cognitive enhancers due to its unique localization and pharmacology. 5-HT6 receptor antagonists have been shown to modulate multiple neurotransmitter systems and therefore enhance cognition in preclinical studies. This premise translated into the clinical efficacy of the 5- HT6 receptor antagonist SB-742457 in mild-to-moderate AD patients. Advances in the understanding of the structureactivity- relationship, the design of novel 5-HT6 receptor ligands and their potential application for the treatment of CI are reviewed.
Export Options
About this article
Cite this article as:
Rosse Gerard and Schaffhauser Herve, 5-HT6 Receptor Antagonists as Potential Therapeutics for Cognitive Impairment, Current Topics in Medicinal Chemistry 2010; 10 (2) . https://dx.doi.org/10.2174/156802610790411036
DOI https://dx.doi.org/10.2174/156802610790411036 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Adaptogens—History and Future Perspectives
Adaptogens are pharmacologically active compounds or plant extracts that are associated with the ability to enhance the body’s stability against stress. The intake of adaptogens is associated not only with a better ability to adapt to stress and maintain or normalise metabolic functions but also with better mental and physical ...read more
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Challenges, Consequences and Possible Treatments of Anticancer Drug Discovery ll
The use of several compounds has been the subject of increasing interest in phytochemistry, biochemistry, and other fields of research at the chemistry-biology-ecosystems interface. In spite of the continued search for new anticancer drugs, cancer remains a leading cause of death. Cancer mortalities are expected to increase to 12.9 million, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Parkinson's Disease: A Role for the Immune System
Current Molecular Pharmacology Ketamine: New Indications for an Old Drug
Current Drug Targets DNAJ Proteins and Protein Aggregation Diseases
Current Topics in Medicinal Chemistry RNA Interference as a Tool for Alzheimers Disease Therapy
Mini-Reviews in Medicinal Chemistry Regulation of Neuronal Cell Death and Neurodegeneration by Members of the Bcl-2 Family: Therapeutic Implications
Current Drug Targets - CNS & Neurological Disorders Drug Targets from Genetics: Alpha-Synuclein
CNS & Neurological Disorders - Drug Targets Differential Kat3 Coactivator Usage Regulates Brain Metabolism and Neuronal Differentiation
Current Molecular Pharmacology Cysteine Network (CYSTEINET) Dysregulation in Parkinson’s Disease: Role of N-acetylcysteine
Current Drug Metabolism Cdk5 in the Adult Non-Demented Brain
Current Drug Targets - CNS & Neurological Disorders Application of Resveratrol in Diabetes: Rationale, Strategies and Challenges
Current Molecular Medicine Contribution of Analytical Microscopies to Human Neurodegenerative Diseases Research (PSP and AD)
Mini-Reviews in Medicinal Chemistry Shikimate Kinase (EC 2.7.1.71) from Mycobacterium tuberculosis: Kinetics and Structural Dynamics of a Potential Molecular Target for Drug Development
Current Medicinal Chemistry “Metabolic Aspects” In Inflammatory Bowel Diseases
Current Drug Delivery Role of Resveratrol and its Analogues in the Treatment of Neurodegenerative Diseases: Focus on Recent Discoveries
CNS & Neurological Disorders - Drug Targets Gene Therapy, A Novel Therapeutic Tool for Neurological Disorders: Current Progress, Challenges and Future Prospective
Current Gene Therapy Cation-Responsive MRI Contrast Agents Based on Gadolinium(III)
Current Inorganic Chemistry (Discontinued) Phase 1 Safety, Tolerability and Pharmacokinetics of 3K3A-APC in Healthy Adult Volunteers
Current Pharmaceutical Design Integrated Analysis of Transcriptomic and Proteomic Data
Current Genomics Current Opinion on 3-[2-[(2-Tert-Butyl-Phenylaminooxalyl)-Amino]-Propionylamino]- 4-Oxo-5-(2,3,5,6-Tetrafluoro-Phenoxy)-Pentanoic Acid, an Investigational Drug Targeting Caspases and Caspase-Like Proteases: The Clinical Trials in Sight and Recent Anti-Inflammatory Advances
Recent Patents on Inflammation & Allergy Drug Discovery One-pot Synthesis of Dihydropyrano[2,3-c]chromenes via a Three-component Reaction in Aqueous Media
Combinatorial Chemistry & High Throughput Screening